Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIA: OSE2101 vs Docetaxel in Advanced NSCLC
NCT06472245Phase 3
Key facts
- Status
- Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 14
- Sponsor
- OSE Immunotherapeutics
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Drugs
- Tedopi
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 3, randomised, open-label trial of Tedopi in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSE Immunotherapeutics. Primary endpoint: Overall Survival at 3 years. Started Dec 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Arm A: OSE2101
OSE2101 monotherapy
Arm B: Docetaxel
Docetaxel monotherapy
03
Who it enrols
Adult patients with HLA-A2 positive metastatic squamous or non-squamous NSCLC with secondary resistance to immune checkpoint inhibitors, without actionable EGFR, ALK, or ROS1 mutations.
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT06472245.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472245.